Franco-Austrian biotech lab Valneva has announced positive results from clinical trials of its Covid vaccine candidate, a month after the UK government terminated a supply deal with the company.

Valneva's VLA2001 vaccine is based on an “inactivated” version of the coronavirus itself to ward off Covid-19, AFP reported.

“This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe and North America,” said Adam Finn, professor of paediatrics at University of Bristol and the chief investigator.

“These results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic,” Finn said in a company statement.